Hyalomatrix: A temporary epidermal barrier, hyaluronan delivery, and neodermis induction system for keratinocyte stem cell therapy

被引:63
作者
Myers, Simon R.
Partha, Vaiude N.
Soranzo, Carlo
Price, Richard D.
Navsaria, Harshad A.
机构
[1] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Cutaneous Res, Cell & Tissue Engn Grp, London E1 2AT, England
[2] Royal London Hosp, Dept Plast & Reconstruct Surg, Barts & London Natl Hlth Serv Trust, London, England
[3] Fidia Adv Biopolymers, Padua, Italy
来源
TISSUE ENGINEERING | 2007年 / 13卷 / 11期
关键词
D O I
10.1089/ten.2007.0109
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Keratinocyte stem cell technology provides at least an adjuvant therapy to clinically close large cutaneous wounds (e. g., burn wounds). Here, the performance of keratinocyte cultures depends primarily on the quality of the bed to which they are applied. Clinical take rates for cultured keratinocyte grafts are optimal when applied to a vascularized dermal bed with minimal bacterial colonization. In the absence of autologous dermis, staged reconstruction with a dermal equivalent or dermal regeneration template is required. A novel product, Hyalomatrix, is a bilayer of an esterified hyaluronan scaffold beneath a silicone membrane. The scaffold delivers hyaluronan to the wound bed, and the silicone membrane acts as a temporary epidermal barrier. The product has been investigated in a controlled, porcine, acute full-thickness excisional wound model. Cultured autologous keratinocytes (CAKs) were delivered on Laserskin to acute full-thickness wounds treated with Hyalomatrix within chambers, and graft take rates were assessed longitudinally using image analysis. In the absence of chambers, wound contraction was assessed. Clinical CAK take rates fall sequentially with delay in application post-Hyalomatrix pre-treatment, but repeated pre-treatment removed this, with maximal take of 57.2% at 5 weeks post-wounding. In the absence of chambers, more-complete wound closure resulted from edge re-epithelialization and contraction, by a factor of 5 at 1 month, and was achieved at least 2 weeks sooner in the gold standard controls of split-thickness autograft to an acute or pre-treated wound bed. Wound contraction and late neodermal morphology (1 year) were similar in pre-treated CAKs and split-thickness autograft wounds. In this model, the Hyalomatrix wound bed pre-treatment increase in CAK take appeared to be dose dependent. The product appeared to act as a hyaluronan delivery system rather than a dermal regeneration template. The silicone membrane may limit wound bed colonization, and the combination of this temporary barrier with hyaluronan delivery and neodermis induction has been termed a barrier-delivery-induction system. The development of similar systems for serial application offers an alternative to a dermal regeneration template when CAKs are engrafted in the hostile, colonized environment of large burn wounds.
引用
收藏
页码:2733 / 2741
页数:9
相关论文
共 40 条
[1]
HEALING OF HYALURONIC-ACID ENRICHED WOUNDS - HISTOLOGICAL OBSERVATIONS [J].
ABATANGELO, G ;
MARTELLI, M ;
VECCHIA, P .
JOURNAL OF SURGICAL RESEARCH, 1983, 35 (05) :410-416
[2]
Review. Hyaluronan: A powerful tissue engineering tool [J].
Allison, David D. ;
Grande-Allen, K. Jane .
TISSUE ENGINEERING, 2006, 12 (08) :2131-2140
[3]
NOMENCLATURE OF HYALURONIC-ACID [J].
BALAZS, EA ;
LAURENT, TC ;
JEANLOZ, RW .
BIOCHEMICAL JOURNAL, 1986, 235 (03) :903-903
[4]
Biocompatibility and biodegradation of different hyaluronan derivatives (Hyaff) implanted in rats [J].
Benedetti, L. ;
Cortivo, R. ;
Berti, T. ;
Berti, A. ;
Pea, F. ;
Mazzo, M. ;
Moras, M. ;
Abatangelo, G. .
Biomaterials, 1993, 14 (15) :1154-1160
[5]
SKIN-GRAFTING - DERMAL COMPONENTS IN INHIBITION OF WOUND CONTRACTION [J].
BROWN, D ;
GARNER, W ;
YOUNG, VL .
SOUTHERN MEDICAL JOURNAL, 1990, 83 (07) :789-795
[6]
Quantitative assessment of the tissue response to films of hyaluronan derivatives [J].
Campoccia, D ;
Hunt, JA ;
Doherty, PJ ;
Zhong, SP ;
ORegan, M ;
Benedetti, L ;
Williams, DF .
BIOMATERIALS, 1996, 17 (10) :963-975
[7]
Semisynthetic resorbable materials from hyaluronan esterification [J].
Campoccia, D ;
Doherty, P ;
Radice, M ;
Brun, P ;
Abatangelo, G ;
Williams, DF .
BIOMATERIALS, 1998, 19 (23) :2101-2127
[8]
Cantor Jerome O., 2006, Inflammation & Allergy Drug Targets, V5, P257, DOI 10.2174/187152806779010936
[9]
Integra as a dermal replacement in a meshed composite skin graft in a rat model: A one-step operative procedure [J].
Chu, CS ;
McManus, AT ;
Matylevich, NP ;
Goodwin, CW ;
Pruitt, BA .
JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE, 2002, 52 (01) :122-129
[10]
CLARKE JA, 1987, LANCET, V1, P983